Arali Ventures

Arali Ventures is a Bengaluru-based pre-seed and seed firm focused on B2B enterprise technology with a deliberate tilt toward AI and deep-tech innovations coming out of India. Check sizes are typically in the $250K to $1M range, positioning the firm as a credible first institutional ticket rather than a Series A lead. Within healthcare, the team is interested in AI/ML applied to clinical and operational workflows and in health IT software sold to providers, payers, and pharma rather than direct-to-consumer plays. The firm reads like an early-stage technology investor that happens to have a healthcare line in its portfolio, not a healthcare specialist, which has implications for what value-add the partners realistically deliver. The right founder profile is an engineering-led team building B2B SaaS or applied AI for the Indian or US enterprise market, with a healthcare angle that fits the firm’s broader pattern recognition around enterprise GTM, sales cycles, and product-led growth. The wrong fit is a clinical-services business, a hardware-heavy medtech device, or a regulated diagnostics platform that needs deep domain operating support. The right entry path is through Bengaluru’s engineering founder community, through accelerators and operator networks tied to ex-Flipkart, Freshworks, and Razorpay alumni, or through warm introductions from co-investors at Blume, 3one4, and Kalaari. Twitter and LinkedIn outbound from technical founders with credible product demos has reportedly worked here, but warm intros remain the higher-yield channel. When pitching, lead with the enterprise GTM motion and the AI capability that genuinely creates a defensible moat; the partners are pattern-matching against B2B SaaS metrics, so customer logos, ACV trajectory, and net retention will be the conversation drivers. Avoid leading with the health-impact narrative; you can layer that in once the commercial story has landed. Caveats: Arali is a small fund, so follow-on capacity is limited, and founders pursuing capital-intensive healthcare models will need to plan a deliberate Series A syndicate beyond the firm’s pro-rata. The firm’s healthcare track record is also still being built, so founders should not expect deep clinical-domain advisory as part of the partnership. Use Arali as a sharp, technically credible early partner for a B2B AI-for-healthcare company, and bring in clinical-specialist capital downstream.